Business / Finance

RSS

Doximity closes $54 million Series C fundraising round

Doximity, the professional network for doctors, today announced closing a $54 million Series C fundraising round co-led by DFJ and funds and accounts managed by T. Rowe Price Associates, Inc. Funds and accounts managed by Morgan Stanley Investment Management also participated in the round as new investors.

29 Apr 2014

Waters reports sales of $431 million for first quarter 2014

Waters Corporation reported today first quarter 2014 sales of $431 million, essentially flat versus sales of $430 million in the first quarter of 2013. In the quarter, the effect of foreign currency translation was neutral to sales growth.

29 Apr 2014

Armetheon reaches agreement with FDA on SPA for final pivotal trial of tecarfarin

Armetheon, Inc., today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the final pivotal trial of tecarfarin.

29 Apr 2014

Bristol-Myers Squibb completes acquisition of iPierian

Bristol-Myers Squibb Company and iPierian, Inc. announced today that Bristol-Myers Squibb has acquired iPierian, a privately held biotechnology company focused on the discovery and development of new treatments for Tauopathies, a class of neurodegenerative diseases associated with the pathological aggregation of Tau protein in the human brain.

29 Apr 2014

Magellan Health Services reports net revenue of $966.5 million for first quarter 2014

Magellan Health Services, Inc. today reported financial results for the first quarter 2014, as summarized below. For the quarter ended March 31, 2014, the company reported net revenue of $966.5 million, segment profit of $76.5 million, and net income of $25.7 million, or $0.92 earnings per share (EPS).

29 Apr 2014

Columbia Laboratories' total revenues increase 15% to $7.2 million in first quarter 2014

Columbia Laboratories, Inc. today announced financial results for the three-month period ended March 31, 2014.

29 Apr 2014

Emilia Group completes acquisition of Pharma Pac's strategic assets

Emilia Group is pleased to announce the recent acquisition of strategic assets of Pharma Pac LLC, an OTC private brand and contract manufacturer, located in DeKalb, MS. The new entity is named Emilia Resources LLC and will operate as a manufacturing company of pharmaceutical and cosmetic products that will combine with Emilia Personal Care's strength in sales, marketing, supply chain and customer service.

28 Apr 2014

Truven Health Analytics announces acquisition of Fortel Analytics' healthcare fraud technology

Truven Health Analytics, a leading provider of healthcare analytics and data solutions and services, today announced the acquisition of Fortel Analytics' healthcare fraud technology. The acquisition gives Truven Health exclusive access to a breakthrough suite of predictive solutions, analysis methods and analytic technology designed to quickly identify suspicious patterns in healthcare insurance claims data before claims are ever paid.

28 Apr 2014

Forest Laboratories enters into definitive agreement to acquire Furiex

Forest Laboratories, Inc. nd Furiex Pharmaceuticals, Inc. today announced that Forest has entered into a definitive agreement to acquire Furiex, a drug development collaboration company, for $95 per share, or approximately $1.1 billion in cash, and up to $30 per share (approximately $360 million in aggregate) in a Contingent Value Right (CVR) that may be payable based on the status of eluxadoline, Furiex's lead product, as a controlled drug following approval.

28 Apr 2014

Voluntis closes €20.75 million ($29 million) Series D financing round

Voluntis, a company pioneering therapeutic companion software, today announced the completion of its Series D financing round. With a total of €20.75 million ($29 million), this fund raising is one of the largest rounds of investment in the m-health sector this year.

28 Apr 2014

Sinovac Biotech commits to commercialize Sabin Inactivated Polio Vaccine in China

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China that focuses on the research, development, manufacturing and commercialization of vaccines, announced today that it has entered into a license agreement with Intravacc (Institute for Translational Vaccinology) from The Netherlands to develop and commercialize the Sabin Inactivated Polio Vaccine (sIPV) for distribution to China and other countries.

28 Apr 2014

Mauna Kea receives regulatory approval in Japan for Cellvizio flagship product

Mauna Kea Technologies, leader in the optical biopsy market, announced today it received regulatory approval in Japan for the company's Cellvizio flagship product.

28 Apr 2014

APCER Pharma's revenues grew by more than 40% in 2013

APCER Pharma, the truly global provider of strategic and outsourced services for clinical safety, pharmacovigilance, medical affairs, and regulatory operations, announced today that revenues grew by more than 40% in 2013 compared to the previous year.

28 Apr 2014

Pernix completes sale of Pernix Manufacturing to Woodfield Pharmaceutical

Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company, today announced that it has closed on the sale of its Houston, TX-based manufacturing operations, Pernix Manufacturing, LLC ("PML") to Woodfield Pharmaceutical LLC.

25 Apr 2014

Swander Pace Capital sells Insight Pharmaceuticals to Prestige Brands Holdings for $750 million

Swander Pace Capital, a leading private equity firm specializing in investments in consumer products companies, announced today that it is selling its over-the-counter (OTC) products portfolio company, Insight Pharmaceuticals, to Prestige Brands Holdings for $750 million.

25 Apr 2014

Covidien net sales increase 3% to $2.60 billion in second quarter fiscal 2014

Covidien plc today announced financial results for the second quarter of fiscal 2014. Second-quarter net sales of $2.60 billion increased 3% from the $2.53 billion in the second quarter a year ago. Operational sales growth was 4% in the second quarter, as foreign exchange rate movement lowered the quarterly sales growth rate by just over one percentage point.

25 Apr 2014

Alimera Sciences inks Loan and Security Agreement with Hercules Technology Growth Capital

Alimera Sciences, Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that its United Kingdom subsidiary, Alimera Sciences Limited, has entered into a Loan and Security Agreement with Hercules Technology Growth Capital, Inc. for a term loan in the principal amount of up to $35 million.

25 Apr 2014

LifePoint Hospitals' first quarter 2014 revenues up 8.2%

LifePoint Hospitals, Inc. today announced results for the first quarter ended March 31, 2014.

25 Apr 2014

Prestige Brands Holdings signs agreement to acquire Insight Pharmaceuticals for $750 million

Prestige Brands Holdings, Inc. today announced that it has entered into a definitive agreement to acquire Insight Pharmaceuticals Corporation, a marketer and distributor of feminine care and other over-the-counter ("OTC") healthcare products, for $750 million in cash.

25 Apr 2014

Biogen Idec's revenue increases 51% to $2.1 billion in first quarter 2014

Biogen Idec Inc. today reported first quarter 2014 results, including revenue of $2.1 billion, a 51% increase compared to the first quarter of 2013.

23 Apr 2014

Business / Finance

Doximity closes $54 million Series C fundraising round

Waters reports sales of $431 million for first quarter 2014

Armetheon reaches agreement with FDA on SPA for final pivotal trial of tecarfarin

Bristol-Myers Squibb completes acquisition of iPierian

Magellan Health Services reports net revenue of $966.5 million for first quarter 2014

Columbia Laboratories' total revenues increase 15% to $7.2 million in first quarter 2014

Emilia Group completes acquisition of Pharma Pac's strategic assets

Truven Health Analytics announces acquisition of Fortel Analytics' healthcare fraud technology

Forest Laboratories enters into definitive agreement to acquire Furiex

Voluntis closes €20.75 million ($29 million) Series D financing round

Sinovac Biotech commits to commercialize Sabin Inactivated Polio Vaccine in China

Mauna Kea receives regulatory approval in Japan for Cellvizio flagship product

APCER Pharma's revenues grew by more than 40% in 2013

Pernix completes sale of Pernix Manufacturing to Woodfield Pharmaceutical

Swander Pace Capital sells Insight Pharmaceuticals to Prestige Brands Holdings for $750 million

Covidien net sales increase 3% to $2.60 billion in second quarter fiscal 2014

Alimera Sciences inks Loan and Security Agreement with Hercules Technology Growth Capital

LifePoint Hospitals' first quarter 2014 revenues up 8.2%

Prestige Brands Holdings signs agreement to acquire Insight Pharmaceuticals for $750 million

Biogen Idec's revenue increases 51% to $2.1 billion in first quarter 2014

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Latest News